News Ticker

WIRE: Growblox forms new division for medical cannabis science

LAS VEGAS — Growblox Sciences, Inc. (OTCQB: GBLX) announced today that it had formed Growblox Life Sciences, LLC, a wholly-owned subsidiary, to pursue development of its intellectual property related to unique cannabis-based medical compounds.

The Company has retained Fenwick & West (http://www.fenwick.com), a Silicon Valley based law firm focusing on life sciences and high technology companies with a nationally top-ranked intellectual property practice, to assist it in the development of strategies for the protection of the Company’s intellectual property.

Growblox Life Sciences, LLC will be a research organization focused on scientific discoveries and applications.  It will not commercially cultivate or sell cannabis.  The Company believes that it has valuable and potentially patentable intellectual property for cannabis-based compounds that will treat a wide range of illnesses, including Parkinson’s Disease.

Growblox CEO John Poss said, “I am very pleased that Fenwick & West has agreed to work with us on these important and potentially medically significant discoveries.  They are clearly one of the leading intellectual property firms in the world.  We know that if they agree to write patents on the fruits of our research and developments, then the patents will be defensible and potentially create great opportunities for commercial development.”

About Growblox Sciences, Inc.
Growblox Sciences, Inc. (GBLX) is a diverse cannabis company, focused on cultivation as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about Growblox Sciences, Inc., go to: http://growblox.com

Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information
Corporate:
Growblox Sciences, Inc.,
3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.comhttp://growblox.com
Investors: John Poss, j.poss@gbsciences.com

SOURCE Growblox Sciences, Inc.

Related Links

http://growblox.com

Leave a comment